ONCOLOGY-NEW YORK

metrics 2024

Shaping the Future of Cancer Treatment Through Knowledge.

Introduction

ONCOLOGY-NEW YORK is a prominent journal dedicated to the field of oncology, published by UBM MEDICA. Since its inception in 1987, the journal has served as a pivotal platform for disseminating groundbreaking research and advancements in cancer treatment, research, and education. With an ISSN of 0890-9091 and an E-ISSN of 2767-7389, it stands as an accessible resource for professionals, researchers, and students alike. The journal currently holds impressive rankings, categorized within Q3 in Oncology and Q4 in Cancer Research for 2023, reflecting its commitment to high-quality research output and contributions to the field. Despite its challenges in Scopus rankings, positioned at #283/404 in Medicine: Oncology and #188/230 in Biochemistry, Genetics, and Molecular Biology: Cancer Research, ONCOLOGY-NEW YORK continues to primarily focus on innovative cancer therapies and emerging clinical research. The journal's ongoing dedication to enhancing knowledge and understanding in oncology makes it a vital resource for all stakeholders invested in combating cancer.

Metrics 2024

SCIMAGO Journal Rank0.34
Journal Impact Factor1.80
Journal Impact Factor (5 years)2.10
H-Index83
Journal IF Without Self1.80
Eigen Factor0.00
Normal Eigen Factor0.20
Influence0.58
Immediacy Index0.30
Cited Half Life10.10
Citing Half Life6.40
JCI0.26
Total Documents4896
WOS Total Citations1612
SCIMAGO Total Citations15380
SCIMAGO SELF Citations174
Scopus Journal Rank0.34
Cites / Document (2 Years)1.14
Cites / Document (3 Years)0.73
Cites / Document (4 Years)0.77

Metrics History

Rank 2024

Scopus

Oncology in Medicine
Rank #283/404
Percentile 29.95
Quartile Q3
Cancer Research in Biochemistry, Genetics and Molecular Biology
Rank #188/230
Percentile 18.26
Quartile Q4

IF (Web Of Science)

ONCOLOGY
Rank 241/322
Percentile 25.30
Quartile Q3

JCI (Web Of Science)

ONCOLOGY
Rank 278/322
Percentile 13.66
Quartile Q4

Quartile History

Similar Journals

Journal of Cancer

Innovative insights for a cancer-free future.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

ESMO Open

Transforming insights into impactful cancer solutions.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

ESMO Open is a premier open-access journal published by Elsevier, dedicated to advancing research in the fields of cancer and oncology. Since its inception in 2016, the journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals, providing a platform for disseminating high-quality, peer-reviewed research. With an impressive Q1 ranking in both Cancer Research and Oncology based on the 2023 category quartiles, ESMO Open ranks within the top tier of its field, showcasing its commitment to excellence and innovation. The journal’s inclusion in Scopus rankings further emphasizes its significant impact, with remarkable placements in the 88th and 83rd percentiles for Oncology and Cancer Research, respectively. Operating under an open access model, ESMO Open ensures that cutting-edge findings and insights are readily available to the global academic community, fostering collaboration and knowledge-sharing to further enhance the understanding and treatment of cancer.

BREAST

Transforming breast cancer care through open access knowledge.
Publisher: CHURCHILL LIVINGSTONEISSN: 0960-9776Frequency: 6 issues/year

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

Onkologie

Pioneering Research for Better Patient Outcomes in Oncology.
Publisher: SPRINGER HEIDELBERGISSN: 2731-7226Frequency: 12 issues/year

Onkologie is a peer-reviewed academic journal published by SPRINGER HEIDELBERG, focusing on the evolving fields of Oncology and Hematology. Established as a significant platform for the dissemination of research in these crucial areas of medicine, Onkologie aims to provide insights into the latest advancements, therapeutic strategies, and clinical practices that shape patient care in oncology and hematology. Despite its current placement in the Q4 category for both disciplines, this journal aspires to foster scholarly dialogues and enhance its contributions to the scientific community. The journal is based in Germany and encourages submissions that promote a deeper understanding of oncology's complex landscape, ensuring that researchers, clinicians, and students have access to a wealth of knowledge essential for clinical practice and further research. With an ISSN of 2731-7226 and E-ISSN of 2731-7234, Onkologie is committed to maintain high standards in publication and peer review, driving innovation and discovery in the fields it represents.

JNCI Cancer Spectrum

Unlocking the future of cancer research and treatment.
Publisher: OXFORD UNIV PRESSISSN: Frequency: 6 issues/year

JNCI Cancer Spectrum, published by Oxford University Press, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. With an impressive impact demonstrated through its Q1 ranking in both Cancer Research and Oncology categories for 2023, this journal provides a vital platform for disseminating high-quality research and innovative findings in a rapidly evolving landscape. Since its inception in 2017, JNCI Cancer Spectrum has embraced open access, enhancing the accessibility of evidence-based knowledge to researchers, professionals, and students across the globe. Additionally, it boasts notable positions in Scopus rankings, with a strong performance in both the Medicine and Biochemistry, Genetics and Molecular Biology categories. The journal is committed to its objectives of fostering collaborative efforts and encouraging dialogue among experts, making it an essential resource for anyone involved in cancer research.

LANCET ONCOLOGY

Pioneering insights in the fight against cancer.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

Oncology in Clinical Practice

Navigating the Landscape of Cancer Treatment
Publisher: VIA MEDICAISSN: 2450-1654Frequency: 6 issues/year

Oncology in Clinical Practice is a vital resource in the field of oncology, published by VIA MEDICA in Poland. This peer-reviewed journal, with ISSN 2450-1654 and E-ISSN 2450-6478, aims to bridge the gap between clinical practice and cancer research, providing a platform for the dissemination of original research, reviews, and case studies. Since its inception in 2019, the journal has featured significant contributions to the understanding of cancer treatment and patient care, although it currently holds a Q4 ranking in Oncology with a Scopus rank of #313/404 and a 22nd percentile in the Medicine _ Oncology category. Though it is not an open-access journal, its content is invaluable for oncologists, researchers, and students, offering critical insights and advancements in clinical approaches to cancer management. With a commitment to enhancing patient outcomes through clinical evidence, Oncology in Clinical Practice serves as an essential reference for those dedicated to the fight against cancer.

World Journal of Clinical Oncology

Exploring Innovations in Clinical Oncology
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

Frontiers in Oncology

Fostering global collaboration in the fight against cancer.
Publisher: FRONTIERS MEDIA SAISSN: 2234-943XFrequency: 1 issue/year

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

Advances in Radiation Oncology

Connecting Ideas, Advancing Oncology
Publisher: ELSEVIER INCISSN: Frequency: 4 issues/year

Advances in Radiation Oncology, published by Elsevier Inc, is a premier international journal dedicated to the field of oncology and radiology, focusing on the latest groundbreaking research and innovations in radiation therapy. Launched as an Open Access journal in 2016, it has since carved out a significant niche in the academic community, featuring contributions that span a diverse range of topics including clinical practices, technologies, and outcomes in radiation oncology. With an impressive Q2 rankingOncology and Radiology, Nuclear Medicine and Imaging categories for 2023, and positioned within the 65th and 55th percentiles of Scopus ranks, it serves as an essential resource for researchers, medical professionals, and students alike. The journal not only emphasizes the importance of disseminating knowledge widely through its open access model but also aims to foster collaboration and innovation in the evolving landscape of cancer treatment. For those looking to stay at the forefront of radiotherapy research and advancements, Advances in Radiation Oncology is an invaluable platform for scholarly communication.